Middle East respiratory syndrome coronavirus: Transmission and phylogenetic evolution

Trends in Microbiology

Volumn 22, Issue 10, 2014, Pages 573-579

  Al Tawfiq, Jaffar A ^a,b   Memish, Ziad A ^c,d  

^a DHAHRAN HEALTH CENTER   (Saudi Arabia)

^b INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c MINISTRY OF HEALTH   (Saudi Arabia)

^d ALFAISAL UNIVERSITY   (Saudi Arabia)

Author keywords

Coronavirus; MERS CoV; Middle East; Pathogenesis

Indexed keywords

DIPEPTIDYL PEPTIDASE IV; GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; INTERLEUKIN 2; INTERLEUKIN 8; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MONOCYTE CHEMOTACTIC PROTEIN 1; RANTES;

CORONAVIRUS; CORONAVIRUS INFECTION; GENETIC ANALYSIS; GEOGRAPHIC DISTRIBUTION; HEALTH CARE PERSONNEL; HUMAN; INFECTION CONTROL; INFECTION RISK; MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS; MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS INFECTION; MOLECULAR EVOLUTION; NONHUMAN; PHYLOGENETIC TREE; REVIEW; RISK ASSESSMENT; SARS CORONAVIRUS; VIRUS CELL INTERACTION; VIRUS ENTRY; VIRUS PATHOGENESIS; VIRUS STRAIN; VIRUS TRANSMISSION; ZOONOSIS; ANIMAL; EVOLUTION; GENETICS; PHYLOGENY; PHYSIOLOGY; TRANSMISSION; VIROLOGY;

ANIMALS; BIOLOGICAL EVOLUTION; CORONAVIRUS INFECTIONS; HUMANS; MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS; PHYLOGENY; ZOONOSES;

EID: 84908485680     PISSN: 0966842X     EISSN: 18784380     Source Type: Journal    
DOI: 10.1016/j.tim.2014.08.001     Document Type: Review

References (89)

1. Zaki A.M., et al. Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. N. Engl. J. Med. 2012, 367:1814-1820.
2. Hijawi B., et al. Novel coronavirus infections in Jordan, April 2012: epidemiological findings from a retrospective investigation. East Mediterr Health J. 2013, 19(Suppl 1):S12-S18.
3. State of knowledge and data gaps of Middle East respiratory syndrome coronavirus (MERS-CoV) in humans. PLoS Curr. 2013, The WHO MERS-CoV Research Group. 10.1371/currents.outbreaks.0bf719e352e7478f8ad85fa30127ddb8.
4. Assiri A., et al. Hospital outbreak of Middle East respiratory syndrome coronavirus. N. Engl. J. Med. 2013, 369:407-416.
5. Omrani A.S., et al. A family cluster of Middle East Respiratory Syndrome Coronavirus infections related to a likely unrecognized asymptomatic or mild case. Int. J. Infect. Dis. 2013, 17:e668-e672.
6. Memish Z.A., et al. Family cluster of Middle East respiratory syndrome coronavirus infections. N. Engl. J. Med. 2013, 368:2487-2494.
7. Memish Z.A., et al. Screening for Middle East Respiratory syndrome coronavirus infection in hospital patients and their health care worker and family contacts: a prospective descriptive study. Clin. Microbiol. Infect. 2014, 20:469-474.
8. Assiri A., et al. Epidemiological, demographic, and clinical characteristics of 47 cases of Middle East respiratory syndrome coronavirus disease from Saudi Arabia: a descriptive study. Lancet Infect. Dis. 2013, 13:752-761.
9. Memish Z.A., et al. Middle East respiratory syndrome coronavirus disease in children. Pediatr. Infect. Dis. J. 2014, 10.1097/inf.0000000000000325.
10. Al-Tawfiq J.A., et al. Middle East respiratory syndrome-coronavirus (MERS-CoV): a case-control study of hospitalized patients. Clin. Infect. Dis. 2014, 59:160-165.
11. Memish Z.A., et al. Community case clusters of Middle East respiratory syndrome coronavirus in Hafr Al-Batin, Kingdom of Saudi Arabia: a descriptive genomic study. Int. J. Infect. Dis. 2014, 23:63-68.
12. Al-Abdallat M.M., et al. Hospital-associated outbreak of Middle East respiratory syndrome coronavirus: a serologic, epidemiologic, and clinical description. Clin. Infect. Dis. 2014, 10.1093/cid/ciu359.
13. Guery B., et al. Clinical features and viral diagnosis of two cases of infection with Middle East respiratory syndrome coronavirus: a report of nosocomial transmission. Lancet 2013, 381:2265-2272.
14. Mailles A., et al. First cases of Middle East respiratory syndrome coronavirus (MERS-CoV) infections in France, investigations and implications for the prevention of human-to-human transmission, France, May 2013. Euro Surveill. 2013, 18:20502.
15. Drosten C., et al. Clinical features and virological analysis of a case of Middle East respiratory syndrome coronavirus infection. Lancet Infect. Dis. 2013, 13:745-751.
16. Buchholz U., et al. Contact investigation of a case of human novel coronavirus infection treated in a German hospital, October-November 2012. Euro Surveill. 2013, 18:20406.
17. Evidence of person-to-person transmission within a family cluster of novel coronavirus infections, United Kingdom, February 2013. Euro Surveill. 2013, 18:20427. Health Protection Agency UK Novel Coronavirus Investigation Team.
18. Puzelli S., et al. Investigation of an imported case of Middle East respiratory syndrome coronavirus (MERS-CoV) infection in Florence, Italy, May to June 2013. Euro Surveill. 2013, 18:20564.
19. Cotton M., et al. Transmission and evolution of the Middle East respiratory syndrome coronavirus in Saudi Arabia: a descriptive genomic study. Lancet 2013, 382:1993-2002.
20. Cotton M., et al. Spread, circulation, and evolution of the Middle East respiratory syndrome coronavirus. mBio 2014, 5:e01062-e1113.
21. AL-Tawfiq J.A., et al. Coronaviruses: SARS and MERS-CoV in travellers. Curr. Opin. Infect. Dis. 2014, 10.1097/QCO.0000000000000089.
22. Pebody R.G., et al. The United Kingdom public health response to an imported laboratory confirmed case of a novel coronavirus in September 2012. Euro Surveill. 2012, 17:20292.
23. Reuss A., et al. Contact investigation for imported case of Middle East respiratory syndrome, Germany. Emerg. Infect. Dis. 2014, 20:620-625.
24. Yang L., et al. MERS-related betacoronavirus in Vespertilio superans bats, China. Emerg. Infect. Dis. 2014, 10.3201/eid2007.140318.
25. Drexler J.F., et al. Ecology, evolution and classification of bat coronaviruses in the aftermath of SARS. Antiviral Res. 2014, 101:45-56.
26. Memish Z.A., et al. Middle East respiratory syndrome coronavirus in bats, Saudi Arabia. Emerg. Infect. Dis. 2013, 19:1819-1823.
27. Reusken C.B., et al. Middle East respiratory syndrome coronavirus neutralising serum antibodies in dromedary camels: a comparative serological study. Lancet Infect. Dis. 2013, 13:859-866.
28. Haagmans B.L., et al. Middle East respiratory syndrome coronavirus in dromedary camels: an outbreak investigation. Lancet Infect. Dis. 2014, 14:140-145.
29. Perera R.A., et al. Seroepidemiology for MERS coronavirus using microneutralisation and pseudoparticle virus neutralisation assays reveal a high prevalence of antibody in dromedary camels in Egypt, June 2013. Euro Surveill. 2013, 18:20574.
30. Hemida M.G., et al. Middle East Respiratory Syndrome (MERS) coronavirus seroprevalence in domestic livestock in Saudi Arabia, 2010 to 2013. Euro Surveill. 2013, 18:20659.
31. Meyer B., et al. Antibodies against MERS coronavirus in dromedary camels, United Arab Emirates, 2003 and 2013. Emerg. Infect. Dis. 2014, 20:552-559.
32. Memish Z.A., et al. Human infection with MERS coronavirus after exposure to infected camels, Saudi Arabia, 2013. Emerg. Infect. Dis. 2014, 20:1012-1015.
33. Chu D.K., et al. MERS coronaviruses in dromedary camels, Egypt. Emerg. Infect. Dis. 2014, 20:1049-1053.
34. Nowotny N., et al. Middle East respiratory syndrome coronavirus (MERS-CoV) in dromedary camels, Oman, 2013. Euro Surveill. 2014, 19:20781.
35. Alexandersen S., et al. Middle East respiratory syndrome coronavirus antibody reactors among camels in Dubai, United Arab Emirates, in 2005. Transbound. Emerg. Dis. 2014, 61:105-108.
36. Reusken C.B.E.M., et al. Geographic distribution of MERS coronavirus among dromedary camels, Africa. Emerg. Infect. Dis. 2014, 10.3201/eid2007.140590.
37. Reusken C.B., et al. Middle East respiratory syndrome coronavirus (MERS-CoV) serology in major livestock species in an affected region in Jordan, June to September 2013. Euro Surveill. 2013, 18:20662.
38. Briese T., et al. Middle East respiratory syndrome coronavirus quasispecies that include homologues of human isolates revealed through whole-genome analysis and virus cultured from dromedary camels in Saudi Arabia. mBio 2014, m5:e01146.
39. Reusken C.B., et al. Middle East respiratory syndrome coronavirus (MERS-CoV) RNA and neutralizing antibodies in milk collected according to local customs from dromedary camels, Qatar, April 2014. Euro Surveill. 2014, 19:20829.
40. Corman V.M., et al. Rooting the phylogenetic tree of MERS-coronavirus by characterization of a conspecific virus from an African Bat. J. Virol. 2014, 10.1128/JVI.01498-14.
41. Nishiura H., et al. Missing information in animal surveillance of MERS-CoV. Lancet Infect. Dis. 2014, 14:100.
42. Al-Tawfiq J.A., et al. Middle East respiratory syndrome novel corona MERS-CoV infection. Epidemiology and outcome update. Saudi Med. J. 2013, 34:991-994.
43. Al-Tawfiq J.A. Middle East respiratory syndrome-coronavirus infection: an overview. J. Infect. Public Health 2013, 6:319-322.
44. Al-Tawfiq J.A., et al. Emerging respiratory viral infections: MERS-CoV and influenza. Lancet Respir. Med. 2014, 2:23-25.
45. Memish Z.A., et al. Hospital-associated Middle East respiratory syndrome coronavirus infections. N. Engl. J. Med. 2013, 369:1761-1762.
46. WHO WHO Statement on the third meeting of the IHR Emergency committee concerning Middle East respiratory syndrome coronavirus (MERS-CoV). Wkly. Epidemiol. Rec. 2013, 88:435-436.
47. Memish Z.A., et al. Middle East respiratory syndrome coronavirus infections in health care workers. N. Engl. J. Med. 2013, 369:884-886.
48. Zumla A., et al. Infection control and MERS-CoV in health-care workers. Lancet 2014, 383:1869-1871.
49. Azhar E.I., et al. Detection of the Middle East respiratory syndrome coronavirus genome in an air sample originating from a camel barn owned by an infected patient. mBio 2014, 5:e01450-e1514.
50. Goh G.K., et al. Prediction of intrinsic disorder in MERS-CoV/HCoV-EMC supports a high oral-fecal transmission. PLoS Curr. 2013, 10.1371/currents.outbreaks.22254b58675cdebc256dbe3c5aa6498b.
51. Drosten C., et al. Identification of a novel coronavirus in patients with severe acute respiratory syndrome. N. Engl. J. Med. 2003, 348:1967-1976.
52. Peiris J.S., et al. Severe acute respiratory syndrome. Nat. Med. 2004, 10(Suppl.):S88-S97.
53. Peiris J.S., et al. The severe acute respiratory syndrome. N. Engl. J. Med. 2003, 349:2431-2441.
54. van Doremalen N., et al. Stability of Middle East respiratory syndrome coronavirus (MERS-CoV) under different environmental conditions. Euro Surveill. 2013, 18:20590.
55. Tomlinson B., et al. SARS: experience at Prince of Wales Hospital, Hong Kong. Lancet 2003, 361:1486-1487.
56. Booth T.F., et al. Detection of airborne severe acute respiratory syndrome (SARS) coronavirus and environmental contamination in SARS outbreak units. J. Infect. Dis. 2005, 191:1472-1477.
57. Raj V.S., et al. Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC. Nature 2013, 495:251-254.
58. Lu G., et al. Molecular basis of binding between novel human coronavirus MERS-CoV and its receptor CD26. Nature 2013, 500:227.
59. Raj V.S., et al. Adenosine deaminase acts as a natural antagonist for dipeptidyl peptidase 4-mediated entry of the Middle East respiratory syndrome coronavirus. J. Virol. 2014, 88:1834-1838.
60. Guan Y., et al. Isolation and characterization of viruses related to the SARS coronavirus from animals in southern China. Science 2003, 302:276e8.
61. van Doremalen N., et al. Host species restriction of middle east respiratory syndrome coronavirus through its receptor dipeptidyl peptidase 4. J. Virol. 2014, 88:9220-9232.
62. Mielech A.M., et al. MERS-CoV papain-like protease has deISGylating and deubiquitinating activities. Virology 2014, 450-451:64-70.
63. Barlan A., et al. Receptor variation and susceptibility to Middle East respiratory syndrome coronavirus infection. J. Virol. 2014, 88:4953-4961.
64. Chan J.F., et al. Differential cell line susceptibility to the emerging novel human betacoronavirus 2c EMC/2012: implications for disease pathogenesis and clinical manifestation. J. Infect. Dis. 2013, 207:1743.
65. Müller M.A., et al. Human coronavirus EMC does not require the SARS-coronavirus receptor and maintains broad replicative capability in mammalian cell lines. mBio 2012, 3:e00515.
66. Zhou J., et al. Active replication of Middle East respiratory syndrome coronavirus and aberrant induction of inflammatory cytokines and chemokines in human macrophages: implications for pathogenesis. J. Infect. Dis. 2014, 209:1331-1342.
67. Siu K.L., et al. Middle East respiratory syndrome coronavirus 4a protein is a double-stranded RNA-binding protein that suppresses PACT-induced activation of RIG-I and MDA5 in the innate antiviral response. J. Virol. 2014, 88:4866-4876.
68. Du L., et al. A truncated receptor-binding domain of MERS-CoV spike protein potently inhibits MERS-CoV infection and induces strong neutralizing antibody responses: implication for developing therapeutics and vaccines. PLoS ONE 2013, 8:e81587.
69. Zhao G., et al. A safe and convenient pseudovirus-based inhibition assay to detect neutralizing antibodies and screen for viral entry inhibitors against the novel human coronavirus MERS-CoV. Virol. J. 2013, 10:266.
70. Ma C., et al. Intranasal vaccination with recombinant receptor-binding domain of MERS-CoV spike protein induces much stronger local mucosal immune responses than subcutaneous immunization: Implication for designing novel mucosal MERS vaccines. Vaccine 2014, 32:2100-2108.
71. Cockrell A.S., et al. Mouse dipeptidyl peptidase 4 is not a functional receptor for Middle East respiratory syndrome coronavirus infection. J. Virol. 2014, 88:5195-5199.
72. Schäfer A., et al. Systems approaches to coronavirus pathogenesis. Curr. Opin. Virol. 2014, 6C:61-69.
73. Faure E., et al. Distinct immune response in two MERS-CoV-infected patients: can we go from bench to bedside?. PLoS ONE 2014, 9:e88716.
74. Jiang L., et al. Potent neutralization of MERS-CoV by human neutralizing monoclonal antibodies to the viral spike glycoprotein. Sci. Transl. Med. 2014, 6:234ra59.
75. Hsieh Y.H., et al. Quarantine for SARS, Taiwan. Emerg. Infect. Dis. 2005, 11:278-282.
76. Wu J.T., et al. Reducing the impact of the next influenza pandemic using household-based public health interventions. PLoS Med. 2006, 3:e361.
77. Lloyd-Smith J.O., et al. Curtailing transmission of severe acute respiratory syndrome within a community and its hospital. Proc. Biol. Sci. 2003, 270:1979-1989.
78. Fraser C., et al. Factors that make an infectious disease outbreak controllable. Proc. Natl. Acad. Sci. U.S.A. 2004, 101:6146-6151.
79. Bondy S.J., et al. Quantifying the impact of community quarantine on SARS transmission in Ontario: estimation of secondary case count difference and number needed to quarantine. BMC Public Health 2009, 9:488.
80. Hsieh Y.H., et al. SARS outbreak, Taiwan, 2003. Emerg. Infect. Dis. 2004, 10:201-206.
81. Dwosh H.A., et al. Identification and containment of an outbreak of SARS in a community hospital. CMAJ 2003, 168:1415-1420.
82. Gopalakrishna G., et al. SARS transmission and hospital containment. Emerg. Infect. Dis. 2004, 10:395-400.
83. Le D.H., et al. Lack of SARS transmission among public hospital workers, Vietnam. Emerg. Infect. Dis. 2004, 10:265-268.
84. Memish Z.A., et al. Middle East respiratory syndrome corona virus, MERS-CoV. Conclusions from the 2nd Scientific Advisory Board Meeting of the WHO Collaborating Center for Mass Gathering Medicine, Riyadh. Int. J. Infect. Dis. 2014, 24:51-53.
85. Memish Z.A., et al. Respiratory tract samples, viral load and genome fraction yield in patients with Middle East respiratory syndrome. J. Infect. Dis. 2014, 10.1093/infdis/jiu292.
86. Al-Tawfiq J.A., et al. Travel implications of emerging coronaviruses: SARS and MERS-CoV. Travel Med. Infect. Dis. 2014, 10.1016/j.tmaid.2014.06.007.
87. Yang Y., et al. Receptor usage and cell entry of bat coronavirus HKU4 provide insight into bat-to-human transmission of MERS coronavirus. Proc. Natl. Acad. Sci. U S A. 2014, [pii: 201405889, Epub ahead of print]. 10.1073/pnas.1405889111.
88. Corman V.M., et al. Antibodies against MERS Coronavirus in Dromedary Camels, Kenya, 1992-2013. Emerg. Infect. Dis. 2014, 10.3201/eid2008.140596.
89. Müller M.A., et al. MERS coronavirus neutralizing antibodies in camels, eastern Africa, 1983-1997. Emerg. Infect. Dis. 2014, 10.3201/eid2012.141026.